SG138623A1 - Use of ppr delta agonists for treating demyelinating diseases - Google Patents

Use of ppr delta agonists for treating demyelinating diseases

Info

Publication number
SG138623A1
SG138623A1 SG200800123-2A SG2008001232A SG138623A1 SG 138623 A1 SG138623 A1 SG 138623A1 SG 2008001232 A SG2008001232 A SG 2008001232A SG 138623 A1 SG138623 A1 SG 138623A1
Authority
SG
Singapore
Prior art keywords
ppr
demyelinating diseases
delta agonists
treating demyelinating
treating
Prior art date
Application number
SG200800123-2A
Other languages
English (en)
Inventor
Karen Chandross
Jean Merrill
Anne Minnich
Lan Lee
Olga Khorkova
Yun Liu
Original Assignee
Aventis Pharmaceuticals Inc Us
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc Us filed Critical Aventis Pharmaceuticals Inc Us
Publication of SG138623A1 publication Critical patent/SG138623A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200800123-2A 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases SG138623A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
SG138623A1 true SG138623A1 (en) 2008-01-28

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200800123-2A SG138623A1 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Country Status (16)

Country Link
US (1) US20070149580A1 (enExample)
EP (1) EP1737440A2 (enExample)
JP (1) JP2007530703A (enExample)
KR (1) KR20060134191A (enExample)
CN (1) CN1950077A (enExample)
AU (1) AU2005231358A1 (enExample)
BR (1) BRPI0509540A (enExample)
CA (1) CA2561159A1 (enExample)
IL (1) IL178165A0 (enExample)
MA (1) MA28561B1 (enExample)
MX (1) MXPA06011218A (enExample)
NO (1) NO20064985L (enExample)
RU (1) RU2006138495A (enExample)
SG (1) SG138623A1 (enExample)
WO (1) WO2005097098A2 (enExample)
ZA (1) ZA200607850B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
CN101336113B (zh) * 2005-11-28 2015-07-29 千寿制药株式会社 包括ppar激动剂的药物
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
CA2727373A1 (en) 2008-06-09 2009-12-17 Sanofi-Aventis Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
US20130117868A1 (en) 2009-12-17 2013-05-09 Sanofi Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo Imaging
DK2675893T3 (en) * 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤

Also Published As

Publication number Publication date
NO20064985L (no) 2006-10-31
WO2005097098A2 (en) 2005-10-20
KR20060134191A (ko) 2006-12-27
CN1950077A (zh) 2007-04-18
IL178165A0 (en) 2008-03-20
US20070149580A1 (en) 2007-06-28
BRPI0509540A (pt) 2007-09-18
CA2561159A1 (en) 2005-10-20
MXPA06011218A (es) 2007-01-16
JP2007530703A (ja) 2007-11-01
WO2005097098A3 (en) 2005-12-22
MA28561B1 (fr) 2007-04-03
AU2005231358A1 (en) 2005-10-20
ZA200607850B (en) 2008-10-29
RU2006138495A (ru) 2008-05-10
EP1737440A2 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
EP2063897A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL197933A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
IL176028A0 (en) Compounds for treatment of cell proliferative diseases
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP2019649A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING BODILUM DISORDER DISORDERS
IL183506A0 (en) Compositions and methods for treating neoplastic diseases
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL178165A0 (en) Use of ppr delta agonists for treating demyelinating diseases
EP1701735A4 (en) METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF DIABETES
EP1709155A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DYSPROLIFERATIVE DISEASES AND METHODS OF THEIR USE
IL179210A0 (en) Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
IL188894A0 (en) Compounds for treatment of lipase-mediated diseases
ZA200604680B (en) Process for the preparation of tubulin inhibitors
PT1742937E (pt) Derivados de pirrolopirimidina úteis para o tratamento de doenças proliferativas
ZA200704971B (en) Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
IL184236A0 (en) Glycine reuptake inhibitors for treatment of drug dependence
ZA200606780B (en) Compounds for the treatment of diseases
IL178990A0 (en) Methods of treating demyelinating disorders
AP2006003728A0 (en) Compounds for treatment of diseases